Clinical case of the development of Sweet's syndrome in a patient with myelodysplastic syndrome
https://doi.org/10.25789/YMJ.2024.86.22
Abstract
Sweet's syndrome is a rare type of dermatoses, which characterized by a recurrent course, painful bright red papules, inflammatory plaques, fever and neutrophilic leukocytosis. The article demonstrates a clinical case of Sweet's syndrome associated with hypomethylating agents in patient with myelodysplastic syndrome. The diagnosis was verified based on clinical features which included purplish-red colored skin plaques with ulcerative-necrotic defects right after azacitidine and decitabine therapy; profound therapeutic effect from steroids, plasmapheresis, ineffectiveness of antibiotics, antifungal drugs; increasing the level of neutrophils. The concurrent severe course of the diseases was complicated by extensive necrotic skin lesions of the lower extremities, which required surgical intervention. The recurrent course of Sweet's syndrome and the ineffectiveness of maintenance doses of prednisolone required a consideration of changing treatment approach of myelodysplastic syndrome with the discontinuation of hypomethylating agents.
Therapeutic tactics for patients with a rare disease, Sweet's syndrome, should be selected individually, taking into account the form of the disease and concomitant pathology.
About the Authors
U. V. Semenova
Semenova Uigulana Vasilevna – student of the Medical Institute
Russian Federation
Russian Federation
M.K. Ammosov North-Eastern Federal University
A. I. Borisov
Borisov Alexey Innokentievich – student of the Medical Institute
Russian Federation
Russian Federation
M.K. Ammosov North-Eastern Federal University
T. N. Alexandrova
National Center of Medicine
Russian Federation
Russian Federation
Aleksandrova Tuiara Nikonovna – hematologist, department of hematology
I. I. Mulina
National Center of Medicine
Russian Federation
Russian Federation
Mulina Inna Ivanovna – head of department of hematology
V. N. Yadrikhinskaya
Medical Institute of M.K. Ammosov North-Eastern Federal University
Russian Federation
Russian Federation
Yadrikhinskaya Vera Nikolaevna – PhD in Medicine, associate professor of the department Hospital therapy, professional diseases, clinical pharmacology
References
1. The idiopathic form of Sweet’s syndrome / O.Yu. Olisova [et al.].russian Journal of Skin and Venereal Diseases. 2016; 19(1): 27-31. doi: 10.18821/1560-9588-2016-19-1-27-31
2. Clinical guidelines. Myelodysplastic syndrome / National hematology society. M., 2020. https://cr.minzdrav.gov.ru/recomend/141/. Assess date: 16.01.2024
3. Autoimmune disorders are common in myelodysplastic syndrome patients and confer an adverse impact on outcomes / J. Montoro [et al.] // Ann Hematol. 2018. Vol. 97, No. 8. Р.1349-1356. doi: 10.1007/s00277-018-3302-0.
4. Barcellini W, Giannotta JA, Fattizzo B. Autoimmune Complications in Hematologic Neoplasms // Cancers (Basel). 2021. Vol. 13, №7. Р.1532. doi: 10.3390/cancers13071532
5. Berry WA, Kelly R. A case of polycyclic Sweet's syndrome arising from azacitidine injection sites in myelodysplasia. Ann Hematol. 2020 Jan;99(1):201-202. doi: 10.1007/s00277-019-03873-x.
6. Chronic immune stimulation might act as a trigger for the development of acute myeloid leukemia or myelodysplastic syndromes /s. Y. Kristinsson [et al.] // 2011. Vol. 29, No. 21. P. 2897-2903. DOI: 10.1200/JCO.2011.34.8540
7. Complete remission of Sweet's syndrome after azacytidine treatment for concomitant myelodysplastic syndrome /s. Martinelli [et al.] // Int J Hematol. – 2014. Vol. 99, No. 5. Р. 663-7. doi: 10.1007/s12185-014-1527-9.
8. New Practical Aspects of Sweet Syndrome / T.P. Joshi, S.K. Friske, D.A. Hsiou [et al] // Am J Clin Dermatol. 2022. Vol. 23. No 3. Р. 301-318. doi: 10.1007/s40257-022-00673-4
9. Paraneoplastic Dermatoses: A Brief General Review and an Extensive Analysis of Paraneoplastic Pemphigus and Paraneoplastic Dermatomyositis / D. Didona [et al.] // Int J Mol Sci. 2020. Vol. 21, No. 6. Р. 2178. doi: 10.3390/ijms21062178
10. Response of autoimmune and inflammatory disorders in myelodysplastic syndromes to 5-azacytidine: report of two cases and literature review/ D.Y. Wu, J. Wang, R. Zhang [et al.] // Ann Palliat Med. 2021. Vol. 10, No. 8. Р. 9276-9280. doi: 10.21037/apm-21-1416.
11. Sweet Syndrome Associated with Myelodysplastic Syndrome-A Review of a Multidisciplinary Approach / C.R. Ferea, S.N. Mihai, G. Balan [et al.] // Life (Basel). 2023. Vol. 13, No. 3. Р. 809. DOI: 10.3390/life13030809
12. Sweet syndrome: long-term follow-up of 138 patients / Clinical and Experimental Dermatology / J. Marcoval, C. Martín-Callizo, F. Valentí-Medina [et al.] // 2016. Vol. 41, No. 7. Р. 741–746. doi: 10.1111/ced.12899.
13. Vasculitis in Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia: A Report of Two Cases / J. Jacobse, Y. W. J. Sijpkens, J.W. van 't Wout [et al.] // J Hematol. 2018. Vol. 7. No. 4. Р. 158-162. doi: 10.14740/jh461w
14. Vashisht P, Goyal A, Hearth Holmes MP. Sweet Syndrome. 2022 Sep 12. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–. PMID: 28613704.
Review
For citations:
Semenova U.V., Borisov A.I., Alexandrova T.N., Mulina I.I., Yadrikhinskaya V.N. Clinical case of the development of Sweet's syndrome in a patient with myelodysplastic syndrome. Yakut Medical Journal. 2024;(2):94-97. https://doi.org/10.25789/YMJ.2024.86.22
Views:
24
Email this article 